How Much Does Mounjaro Cost in 2026?
Mounjaro monthly cost by payment channel
| Channel | Monthly cost |
|---|---|
| Insurance + Mounjaro Savings Card (T2D patient) | $0 to $25 |
| Insurance copay only (no Savings Card) | $25 to $150 |
| Branded telehealth (Hims/Ro/LifeMD) | $499 |
| Compounded tirzepatide (when available) | $299 |
| LillyDirect self-pay (Mounjaro) | N/A |
| Cash retail (full WAC) | $1,069 |
Quick decision tree: which Mounjaro path is yours?
- Do you have a type 2 diabetes diagnosis? If yes, your insurance likely covers Mounjaro with prior auth. Apply for the Mounjaro Savings Card → $25/fill.
- Do you have insurance but no T2D diagnosis? Mounjaro denial is almost certain (off-label). Switch your prescriber to write for Zepbound (same drug, weight-loss indication).
- No insurance at all? Branded telehealth at $499/month is fastest. Or pivot to Zepbound for LillyDirect self-pay vials at $299 to $449/month.
- Medicare/Medicaid + T2D diagnosis? Mounjaro is covered for diabetes. Savings Card does NOT work for government insurance. Standard formulary copays apply.
Mounjaro coverage by major insurer
Coverage stance and per-carrier details for Mounjaro. Each link goes to the full prior-auth requirements, cost table, and appeal playbook for that carrier.
Frequently asked questions
How much does Mounjaro cost per month in 2026?
Range: $25 to $1,069 per month depending on how you pay. With commercial insurance + Mounjaro Savings Card and a type 2 diabetes diagnosis: $25 to $150/month copay. Without insurance, branded telehealth runs $499/month and compounded tirzepatide (when available) runs $299/month. Cash retail at full list price is $1,069/month, which almost no one pays. Eli Lilly does NOT offer a self-pay vial program for Mounjaro the way they do for Zepbound; if you don't have a diabetes diagnosis, switching to Zepbound (same molecule) usually unlocks the LillyDirect $299/month path.
Why is Mounjaro so much harder to get covered than Zepbound?
Mounjaro is FDA-approved for type 2 diabetes only. Zepbound is the same molecule (tirzepatide) FDA-approved for chronic weight management. If you have a documented type 2 diabetes diagnosis, Mounjaro coverage is straightforward and Zepbound coverage is harder. If you do NOT have type 2 diabetes, the reverse is true. Insurers strictly enforce the FDA indication. Trying to get Mounjaro covered for off-label weight loss almost always results in a prior-authorization denial; trying to get Zepbound for type 2 diabetes typically requires a Mounjaro step-therapy first.
How does the Mounjaro Savings Card work?
The Mounjaro Savings Card from Eli Lilly drops your commercial-insurance copay to as little as $25 per fill if your plan covers Mounjaro. Lilly covers up to $150 per month of your insurer copay. Government insurance (Medicare, Medicaid, Tricare, VA, DOD) is excluded by federal anti-kickback statute. The card runs through 12/31/2026 with up to 13 fills per 12-month period. You apply at lilly.com/mounjaro/savings-and-resources.
Is Mounjaro available on LillyDirect like Zepbound?
No. LillyDirect's discounted self-pay vial program (currently $299 to $449/month) is exclusive to Zepbound. Mounjaro is not available through that program because Eli Lilly markets Mounjaro for diabetes patients who typically have insurance coverage, and Zepbound for chronic weight management where the cash-pay market is bigger. If you want the LillyDirect price for tirzepatide, your prescriber needs to write for Zepbound instead of Mounjaro - same molecule, different brand, dramatically different cash-pay options.
What is compounded tirzepatide and is it still legal in 2026?
Compounded tirzepatide is a non-FDA-approved version manufactured by 503A or 503B compounding pharmacies, typically prescribed via telehealth platforms like Hims and Ro. Historically priced around $199 to $299/month, much cheaper than branded. Legal status narrowed sharply in 2025-2026: FDA ended enforcement discretion for 503B (March 2025) and 503A (February 2025) after the official tirzepatide shortage was declared resolved. On April 30, 2026, the FDA proposed adding tirzepatide to the 503B Bulks List exclusion. 503A retains a narrow individual-patient exception for documented allergy or specific clinical justification; cost savings alone does not qualify. Hims and Ro have largely shifted to branded drugs as a result.
How does Mounjaro cost compare to Ozempic for type 2 diabetes?
Both are FDA-indicated for T2D and both have similar copay-card structures (~$25 with commercial insurance + savings card). Mounjaro lists at $1,069/month, Ozempic at $998/month. Mounjaro produces meaningfully more weight loss in trials (20.9% peak vs 11.6% for Ozempic). Most patients with T2D do better on Mounjaro for combined glycemic control + weight loss. Ozempic is sometimes preferred for cardiovascular benefit (SUSTAIN-6 outcomes data) and longer real-world track record (FDA approval since 2017 vs Mounjaro 2022).
What if my insurance denies Mounjaro for weight loss?
Expected and common - Mounjaro is not FDA-indicated for weight loss, so insurers will deny prior auth requests citing the off-label indication. Three real options: (1) Switch to Zepbound (same molecule, FDA-indicated for weight loss; insurance may still deny but at least you can argue the on-label use); (2) LillyDirect self-pay vials for Zepbound at $299 to $449/month; (3) If you have prediabetes (HbA1c 5.7-6.4) or borderline diabetes, get tested - a documented diagnosis upgrade may unlock Mounjaro coverage for the FDA-indicated use.
Does Medicare or Medicaid cover Mounjaro?
Medicare Part D covers Mounjaro for type 2 diabetes (it does NOT cover GLP-1s prescribed for weight loss alone, which is the federal Medicare statutory exclusion). Medicaid varies by state but most state Medicaid programs cover Mounjaro for T2D. Neither covers Mounjaro for off-label weight loss. The Mounjaro Savings Card does NOT work for Medicare/Medicaid patients regardless of indication, due to federal anti-kickback law.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.